隔离四肢输液用于四肢威胁的不可切除肉 Saroma:过去的进展,当前的应用和未来的方向
Danielle K DePalo1, Jonathan S Zager1
1Department of Cutaneous Oncology, Moffitt Canter, Tampa, FL 33612, USA.
Journal of clinical medicine
|June 28, 2023
概括
软组织肉瘤 (STSs) 具有挑战性治疗. 隔离四肢输液 (ILI) 为四肢STS提供区域化疗,可能挽救四肢,但需要更多的研究.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医学瘤学 医学瘤学
背景情况:
- 软组织肉瘤 (STSs) 由于异质性和最近进展的有限益处,因此存在治疗挑战.
- 切除术是切除性STS的标准,但不可切除的病例需要多式模式的策略.
- 隔离四肢输注 (ILI) 是对四肢STS的区域化疗方法,旨在挽救四肢.
研究的目的:
- 对软组织肉瘤 (STSs) 进行隔离四肢输液 (ILI) 的当前文献进行审查.
- 提供患者资格概述,程序细节,以及有关STS中的ILI的现有出版物.
- 确定未来的研究方向和推动STS治疗中的ILI发展的机会.
主要方法:
- 关于软组织肉瘤 (STSs) 隔离四肢输液 (ILI) 研究的文献综述.
- 分析患者选择标准,程序技术和相关出版物中报告的结果.
- 综合现有数据以确定缺口和未来的研究需求.
主要成果:
- ILI是一种用于四肢STS的区域化疗技术,提供肢体救援潜力.
- 尽管使用了近30年,但关于STS的ILI的文献仍然有限.
- 该审查涵盖了患者的资格,程序,关键出版物和未来的机会.
结论:
- ILI是极端STS的可行的区域方法,特别是在不可切除或局部发达的疾病中.
- 需要进一步的研究来优化ILI协议,并充分理解其在多式联络性STS治疗中的作用.
- 本次审查强调需要对ILI疗效和STS患者选择进行更全面的研究.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


